Vol. 1 No. 8 (2021)
Reimbursement Recommendations

Human Insulin (Entuzity KwikPen)

Published August 23, 2021

Key Messages

  • CADTH recommends that Entuzity KwikPen should be reimbursed by public drug plans to improve glycemic control in adults and children with diabetes mellitus, if certain conditions are met.
  • Entuzity KwikPen should only be reimbursed if it is initiated by a specialist with experience in treating severe insulin resistance and if the cost of Entuzity KwikPen does not exceed the least expensive basal or bolus combination insulin pens or cartridges.
  • Entuzity KwikPen should only be covered to treat patients with diabetes mellitus with unacceptable glycemic control who require more than 200 units of insulin per day, with or without other therapies.